Oncocyte Corp Files 8-K: Agreements, Sales, and Disclosures
Ticker: IMDX · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1642380
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Oncocyte Corp signed new deals, terminated old ones, and sold stock on Feb 6th. Big moves happening.
AI Summary
On February 6, 2025, Oncocyte Corporation entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including the execution of new agreements and the sale of equity, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, termination of agreements, and unregistered sales of equity, suggesting significant corporate activity that could carry inherent risks.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- February 6, 2025 (date) — Earliest event reported
- California (jurisdiction) — State of incorporation
FAQ
What was the nature of the material definitive agreement entered into by Oncocyte Corporation on February 6, 2025?
The filing indicates that Oncocyte Corporation entered into a material definitive agreement on February 6, 2025, but the specific details of this agreement are not provided in the provided text.
What was the reason for the termination of a material definitive agreement by Oncocyte Corporation?
The filing states that Oncocyte Corporation terminated a material definitive agreement on February 6, 2025, but the specific reasons for this termination are not detailed in the provided text.
Did Oncocyte Corporation engage in unregistered sales of equity securities?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information, indicating such sales occurred.
What is the primary business of Oncocyte Corporation?
Oncocyte Corporation is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' as indicated by its Standard Industrial Classification code.
When was Oncocyte Corporation incorporated?
Oncocyte Corporation was incorporated in California, as stated in the filing.
Filing Stats: 2,105 words · 8 min read · ~7 pages · Grade level 13.6 · Accepted 2025-02-10 09:17:01
Key Financial Figures
- $0.0001 — Common Stock, with an exercise price of $0.0001 per share. The purchase price for one C
- $2 — purchase price for one Common Share was $2.05, and the purchase price for one Pre-
- $2.05 — se price for one Pre-Funded Warrant was $2.05. The closing of the Private Placement i
- $21.7 m — cement are expected to be approximately $21.7 million, before estimated offering expens
- $7.4 m — fering are expected to be approximately $7.4 million, before estimated offering expens
- $7,500,000 — from time to time up to an aggregate of $7,500,000 of Common Stock through Needham in tran
- $1.8 million — ement, the Company sold an aggregate of $1.8 million of its Common Stock under the Sales Agr
Filing Documents
- form8-k.htm (8-K) — 61KB
- ex4-1.htm (EX-4.1) — 107KB
- ex5-1.htm (EX-5.1) — 16KB
- ex10-1.htm (EX-10.1) — 219KB
- ex10-2.htm (EX-10.2) — 169KB
- ex10-3.htm (EX-10.3) — 262KB
- ex99-1.htm (EX-99.1) — 23KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- ex5-1_002.jpg (GRAPHIC) — 2KB
- 0001493152-25-005563.txt ( ) — 1212KB
- ocx-20250206.xsd (EX-101.SCH) — 3KB
- ocx-20250206_lab.xml (EX-101.LAB) — 33KB
- ocx-20250206_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: February 10, 2025 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer